

Carboxylic acid derivatives of amlexanox display enhanced potency towards TBK1 and IKK ϵ and reveal mechanisms for selective inhibition

Tyler S. Beyett, Xinmin Gan, Shannon M. Reilly, Louise Chang, Andrew V. Gomez, Alan R.
Saltiel, Hollis D. Showalter, and John J. G. Tesmer

Program in Chemical Biology (T.S.B.), Life Sciences Institute (T.S.B., L.C., and J.J.G.T.),
Departments of Medicinal Chemistry (X.G., H.D.S., J.J.G.T.), Pharmacology (J.J.G.T.),
Biological Chemistry (J.J.G.T.), and Vahlteich Medicinal Chemistry Core, College of Pharmacy
(X.G. and H.D.S.), University of Michigan, Ann Arbor, Michigan. Institute for Diabetes and
Metabolic Health (S.M.R., A.V.G., and A.R.S.), Departments of Medicine (S.M.R. and A.R.S.),
and Pharmacology (A.V.G. and A.R.S.), University of California, San Diego, La Jolla,
California.

Running Title Page

- a) Amlexanox carboxylic acid structure-activity analysis

Corresponding author:

John J. G. Tesmer, Ph.D.

Purdue University

240 S. Martin Jischke Drive, Room 329

West Lafayette IN 47907-2054

Tel. (765) 494-1807

Email: jtesmer@purdue.edu

- b) Number of text pages (including abstract): 29

Number of tables: 2

Number of schemes: 2

Number of figures: 3

Number of references: 28

Number of words in abstract: 213

Number of words in introduction: 556

Number of words in discussion: 1224

- c) List of nonstandard abbreviations: AMPK, AMP-activated protein kinase; I κ B, Inhibitor of NF- κ B; IKK, I κ B kinase; IL-6, interleukin-6; MAPK, mitogen-activated protein kinase; NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells; P-loop, Phosphate-binding loop; TBK1, TANK-binding kinase 1; SAR, structure-activity relationship

Abstract

Chronic, low-grade inflammation is a hallmark of obesity, which is a risk factor for the development of type 2 diabetes. The drug amlexanox inhibits inhibitor of κ B kinase ϵ (IKK ϵ) and TANK binding kinase 1 (TBK1) to promote energy expenditure and improve insulin sensitivity. Recent clinical studies have demonstrated efficacy in a subset of diabetic patients with underlying adipose tissue inflammation, albeit with moderate potency, necessitating the need for improved analogs. Herein we report crystal structures of TBK1 in complex with amlexanox and a series of analogs that modify its carboxylic acid moiety. Removal of the carboxylic acid or mutation of the adjacent Thr156 residue significantly reduces potency toward TBK1, whereas conversion to a short amide or ester nearly abolishes inhibitory effects. IKK ϵ is less affected by these modifications, possibly due to variation in its hinge residues allowing for increased conformational plasticity. Installation of a tetrazole carboxylic acid bioisostere improved potency to 200 and 400 nM towards IKK ϵ and TBK1, respectively. Despite improvements in *in vitro* potency, no analog produced a greater response in adipocytes than amlexanox, perhaps because of altered absorption and distribution. The structure-activity relationships (SAR) and co-crystal structures described herein will aid in future structure-guided inhibitor development utilizing the amlexanox pharmacophore for the treatment of obesity and type 2 diabetes.

Introduction

Globally, over 2 billion people are clinically overweight or obese (Swinburn *et al.*, 2011). Obesity is the leading risk factor for the development of type 2 diabetes, and is characterized by chronic, low-grade inflammation in liver and adipose tissues, which in turn attenuates the actions of multiple hormones to produce a dysregulated metabolic state (Reilly *et al.*, 2017; Saltiel, 2016; Mowers *et al.*, 2013). Feeding mice a high fat diet results in increased expression of I κ B kinase ϵ (IKK ϵ) and TANK-binding kinase 1 (TBK1), non-canonical I κ B kinases that attenuate adrenergic receptor-mediated thermogenic signaling (Mowers *et al.*, 2013; Chiang *et al.*, 2009) and AMP-activated protein kinase (AMPK) activation (Zhao *et al.*, 2018). The result is a feed-forward mechanism that promotes additional weight gain and further reduces insulin sensitivity.

Most FDA-approved therapies for obesity focus on reducing caloric intake or altering the neurological reward system associated with eating (Saltiel, 2016). However, recognition that inflammation is involved in the progression of obesity and type 2 diabetes has led to an interest in pharmacologically targeting key components of inflammatory pathways. Several years ago, the FDA-approved asthma and aphthous ulcer drug amlexanox (Makino *et al.*, 1987; Bell, 2005) was identified as an inhibitor of IKK ϵ and TBK1 (Reilly *et al.*, 2013). When administered to obese mice, catecholamine-stimulated cAMP levels are restored, activating p38 mitogen-activated protein kinase (MAPK) and inducing expression of uncoupling protein 1 (*Ucp1*) in adipose tissue, which leads to weight loss via increased energy expenditure (Reilly *et al.*, 2015). Insulin sensitivity and regulation of glucose levels were also improved due to activation of the hepatic JAK/STAT pathway by interleukin-6 (IL-6) whose expression is regulated by cAMP levels in adipocytes (Reilly *et al.*, 2015). Given the history of safety using amlexanox (Bell, 2005), clinical trials in obese and diabetic patients were conducted in which a subset of patients

was identified for their positive response to amlexanox treatment (Oral *et al.*, 2017). These patients showed improvements in hemoglobin A1c, insulin sensitivity, and displayed a reduction in hepatic steatosis while exhibiting changes in energy expenditure gene expression similar to those previously noted in animal studies.

Despite these promising results, the future use of amlexanox in the clinic for obesity and type 2 diabetes intervention will likely be hampered by its limited solubility, as the drug was originally formulated as a topical paste (Bell, 2005), and its moderate potency (Reilly *et al.*, 2013). We demonstrate *in vitro* that the carboxylic acid on amlexanox strongly contributes to potency against TBK1, whereas its elimination enhances potency towards IKK ϵ . Replacement of the carboxylic acid with a tetrazole acid bioisostere results in improved potency towards both kinases, whereas conversion to a methyl amide selectively diminished potency towards TBK1, suggesting a route for the development of IKK ϵ -selective inhibitors. To understand how amlexanox interacts with this family of kinases and to interpret these results, the co-crystal structure of amlexanox bound to TBK1 was determined. This structure suggested a favorable interaction between the carboxylate on amlexanox and the Thr156 side chain in the active site that likely contributes to the potency of inhibition of IKK ϵ and TBK1. Three additional amlexanox analog co-crystal structures shed light on how carboxylate analogs either improve or diminish potency. Together, these results provide the first insights into how to design improved amlexanox analogs for as leads for the treatment of type 2 diabetes and obesity.

Materials and Methods

Synthesis. Experimental procedures are provided in the supplemental methods, including literature citations for all synthetic methodologies utilized. All starting monomers were obtained

from commercial suppliers and were used without further purification. Amlexanox (**1**), >99% pure by HPLC, was purchased from Ontario Chemicals, Inc. 2-Amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile (**8**) was purchased from Aldrich (St. Louis, MO). Routine ¹H NMR spectra were recorded at 400 or 500 MHz on Varian 400 or 500 instruments, respectively, with chloroform-*d* or DMSO-*d*₆ as solvent. Chemical shift values are recorded in δ units (ppm). Mass spectra were recorded on a Micromass TofSpec-2E Matrix-Assisted, Laser-Desorption, Time-of-Flight Mass Spectrometer (Waters Corp., Milford, MA) in a positive ESI mode unless otherwise noted. High resolution mass spectrometry analysis was performed on an Agilent Q-TOF system (Santa Clara, CA). Analytical HPLC was performed on an Agilent 1100 series instrument with an Agilent Zorbax Eclipse Plus C18 (4.6 × 75 mm, 3.5 μm particle size) column with the gradient 10% acetonitrile/water (1 min), 10–90% acetonitrile/water (6 min), and 90% acetonitrile/water (2 min) flow = 1 mL min⁻¹. Thin-layer chromatography was performed on silica gel GHLF plates (250 μm) purchased from Analtech (Newark, DE). Column chromatography was carried out in the flash mode utilizing silica gel (220–240 mesh) purchased from Silicycle (Quebec City, Québec). Extraction solutions were dried over anhydrous sodium sulfate prior to concentration.

Protein Expression and Purification. Human TBK1 and IKKε spanning residues 1-657 were cloned into a modified pFastBac vector (pH7pFB, high-throughput protein lab at the University of Michigan) containing a tobacco etch virus (TEV) protease cleavable N-terminal 6His tag via ligation-independent cloning. Mutagenesis was performed using the QuickChange site-directed mutagenesis protocol (Agilent Technologies, Santa Clara, CA). Positive clones were verified by Sanger sequencing, the DNA transformed into DH10Bac *Escherichia coli*, and bacmid containing the gene of interest isolated by isopropanol precipitation. Recombinant

baculovirus was prepared by transfecting Sf9 insect cells with purified bacmid and passaging several times to obtain virus of a higher titer. For expression, Sf9 or Hi5 insect cells (Invitrogen, Carlsbad, CA) at a density of 2×10^6 cells mL^{-1} were infected with baculovirus and harvested after 65-72 h. Cells were pelleted and flash frozen in liquid nitrogen.

All protein variants were purified using the following protocol. Cell pellets were thawed and resuspended in lysis buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 40 mM imidazole, 1 mM DTT, 0.1 mM phenylmethanesulfonylfluoride (PMSF), leupeptin, and lima bean trypsin protease inhibitor. Resuspended cells were homogenized with a Dounce homogenizer prior to brief sonication. The lysate was clarified by ultracentrifugation for 1 h at $>200,000 \times g$. The resulting supernatant was glass filtered prior to being slowly flowed through Ni-NTA resin. The resin was washed with lysis buffer and the protein eluted with lysis buffer supplemented with an additional 200 mM imidazole. IKK ϵ was purified via anion exchange chromatography and eluted with a NaCl gradient from 0.0-1.0 M at pH 7.5 and protein of $>95\%$ purity by SDS-PAGE concentrated to ~ 1 mg mL^{-1} by absorbance at 280 nm using the calculated IKK ϵ molecular weight and molar extinction coefficient 76,610 kDa and $57,300 \text{ M}^{-1} \text{ cm}^{-1}$, respectively, and flash frozen in liquid nitrogen.

TBK1 was further purified by anion exchange chromatography using a HiTrap Q column and eluted with a NaCl gradient from 0.0-1.0 M at pH 7.5. TBK1 to be used for kinase assays was concentrated to ~ 1 mg mL^{-1} by absorbance at 280 nm using the TBK1 molecular weight and molar extinction coefficient 75,650 kDa and $78,730 \text{ M}^{-1} \text{ cm}^{-1}$, respectively, and flash frozen in liquid nitrogen. TBK1 from anion exchange to be used for crystallography was incubated at 4°C overnight with $\sim 10\%$ (w/w) TEV protease while being dialyzed against 1 L of 20 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT in 6-8,000 kDa cutoff dialysis tubing to cleave the 6His

tag. The following day, the mixture was passed through Ni-NTA resin to remove TEV protease. The cleaved TBK1 protein was dephosphorylated by incubating at room temperature for 4-6 h with λ phosphatase (New England Biolabs, Ipswich, MA) in buffer supplemented with 1 mM MnCl₂. The dephosphorylated protein was further purified via size-exclusion chromatography on an S200 column in buffer lacking MnCl₂ (20 mM HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT). Purified TBK1 for crystallography was concentrated to ~3 mg mL⁻¹ as determined by absorbance at 280 nm, and flash frozen in liquid nitrogen.

Crystallization and Structure Determination. Crystallization conditions were based on those previously reported with modification (Tu *et al.*, 2013; Larabi *et al.*, 2013). TBK1·amlexanox crystals were grown at 20 °C via hanging drop vapor diffusion in drops containing 1 μ L of 0.1 M HEPES pH 7.5, 4% (w/v) PEG 8,000, 2 μ L of purified wild-type human TBK1 (residues 1-657 at ~3 mg mL⁻¹), and 0.2 μ L amlexanox (10 mM in DMSO) over wells containing 1 mL of 0.1 M HEPES pH 7.5, 4% (w/v) PEG 8,000, and 10% DMSO. To obtain TBK1 crystals in complex with the ethyl ester (**3**), tetrazole (**9**), or amide-coupled tetrazole (**5a**) analogs of amlexanox, TBK1 was incubated with 1 mM inhibitor (from 100 mM stock in DMSO) for 1 h on ice. Crystals were grown at 20 °C via hanging drop vapor diffusion in drops containing 1 μ L of well solution and 1 μ L of purified wild-type human TBK1 (residues 1-657 at ~3 mg mL⁻¹) over wells containing 1 mL of 0.1 M HEPES pH 7.0-8.5 and 1-6% (w/v) PEG 8,000. Small diamonds \leq 25 μ m appeared within 1-2 d and grew for an additional 1-3 d to 50-100 μ m in all dimensions. Crystals were harvested and briefly soaked in a cryoprotecting solution composed of 0.1 M HEPES pH 8.5, 8% (w/v) PEG 8,000, 30% (v/v) PEG 400, and 0.5 mM inhibitor prior to flash freezing in liquid nitrogen.

Data were collected at LS-CAT (Advanced Photon Source, Argonne National Lab) under a cryostream maintained at 100 K using either a MAR300 or an Eiger 9M detector. All individual software were used as part of the SBCGrid package (Morin *et al.*, 2013). Data were processed with XDS (Kabsch, 2010) and the structure solved in Phenix (Adams *et al.*, 2010) through molecular replacement implemented by Phaser (McCoy, *et al.* 2007) with a ligand-free structure of TBK1 (PDB 4IM0) as the search model. Models were built by alternating rounds of manual model building in Coot (Emsley *et al.*, 2010) with reciprocal space refinement in Phenix alongside validation with MolProbity (Chen *et al.*, 2010). Ligand restraints were generated with eLBOW in Phenix using the AM1/RM1 semi-empirical quantum-mechanical optimization method (Moriarty *et al.*, 2009). Graphics were prepared with PyMol version 1.6 (Schrödinger, LLC, New York, NY). Coordinates and diffraction amplitudes have been deposited in the Protein Data Bank with the accession codes 5W5V, 6BNY, 6BOD, and 6BOE.

Radiometric Dose-Response Assays. Reactions containing 50 nM TBK1 or IKK ϵ and 5 μ M bovine myelin basic protein (MyBP, EMD Millipore, Billerica, MA) in reaction buffer (50 mM HEPES pH 7.5, 10 mM NaCl, 10 mM MgCl₂, and 1 mM DTT) with varying concentrations of inhibitor were initiated with 5 μ M ATP spiked with [γ -³²P]-ATP (Perkin Elmer, Waltham, MA) and allowed to proceed for 30 min at room temperature in a final volume of 20 μ L. Reactions were quenched with SDS gel loading dye, run on 4-15% SDS-PAGE gels, and imaged on phosphor screens using a Typhoon imager (GE Healthcare, Chicago, IL). Band intensities corresponding to phosphorylated MyBP were quantified with ImageQuant and the intensities normalized to account for variation in scan intensities. The data were analyzed in GraphPad Prism 7 using a three parameter dose-response curve model with the Hill slope constrained to 1

and automatic outlier rejection. Statistical significance determined in GraphPad Prism via two-way ANOVA with Dunnett's multiple comparison correction relative to amlexanox (n=3).

Thermal Shift Assay. Differential Scanning Fluorometry (DSF) was performed in an HT7900 qPCR instrument (ThermoFisher, Waltham, MA) using 0.2 mg mL⁻¹ (2.6 μM) TBK1 in assay buffer (20 mM HEPES pH 8.0, 5 mM MgCl₂, and 1 mM DTT), SYPRO Orange protein gel stain (1000x stock, Sigma-Aldrich), and 200 μM inhibitor. Melt curves were obtained by increasing the temperature from 25-60 °C at a rate of 2 °C min⁻¹. Data were plotted in GraphPad Prism 7 with the inflection point of the sigmoidal curve representing the melting point (T_m) of the protein. The experiment was performed three times in duplicate using protein from the same purification. Statistical significance was assessed via two-way ANOVA with Bonferroni correction for multiple comparisons (n=2).

Solubility Determination. Amlexanox (20 mg) is completely dissolved in 0.35 mL 200 mM NaOH at room temperature by vibration with ultrasonic apparatus, 0.50 mL of PEG-400 added and shaken, and 0.15 mL of PBS buffer (pH=7.4) added and the mixture is shaken by hand again resulting in a clear aqueous solution of amlexanox. Analog **9** (2 mg) or **11** (<1 mg) is completely dissolved in 0.62 mL 10 mM NaOH at room temperature, 0.18 mL 25 mM Tris-HCl buffer (pH=7.6) is added.

3T3-L1 Differentiation. 3T3-L1 fibroblasts (American Type Culture Collection, Manassas, VA) were cultured in DMEM containing 10% FBS. Once grown to confluence, adipocyte differentiation was initiated using a three component cocktail containing 500 μM 3-isobutyl-1-methylxanthine, 250 nM dexamethasone, and 1 μg mL⁻¹ insulin for the first 3 d, followed by an additional 3 d in media containing insulin, and finally differentiation was completed in the culture media. Only cultures in which >90% of cells displayed adipocyte

morphology were used. Fully differentiated adipocytes, which had been cultured in the FBS only media for 1 wk, were treated with 100 μ M amlexanox analog, amlexanox, or vehicle control. Cells were harvested after 1 h of treatment for western blot analysis. Media was collected after 4 h of treatment for IL-6 measurement.

Western Blot Analysis. Cells were homogenized in 50 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM DTT, 1 mM Na₃VO₄, 5 mM NaF, 1 mM PMSF, 25 mM glycerol 2-phosphate, and freshly added protease inhibitor tablet, and then incubated them for 1 h at 4 °C. Cell lysates were produced in an SDS lysis buffer (100 mM Tris pH 7.5, 130 mM NaCl, 1% NP-40, 0.1% SDS, 0.2% sodium deoxycholate, 1 mM Na₃VO₄, 1 mM NaF, 100 mM Na₄P₂O₇, 1 mM PMSF, 25 mM glycerol 2-phosphate, and freshly added protease inhibitor tablet) and sonicated for three 5 s pulses at an output power of 6 W. Crude lysates were centrifuged at 14,000xg for 15 m twice and the protein concentration was determined using Bio-Rad Protein Assay Dye Reagent. Samples were diluted in SDS sample buffer. Bound proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). Individual proteins were detected with specific antibodies and visualized on film using horseradish peroxidase-conjugated secondary antibodies (Bio-Rad) and Western Lightning Enhanced Chemiluminescence (Perkin Elmer Life Sciences). Antibodies TBK1 (3013), phosphorylated TBK1 (Ser172-5483), p38 (9212), and phosphorylated p38 (Thr180/Tyr182-9211) were purchased from Cell Signaling Technology (Danvers, MA).

IL-6 measurement. Il-6 levels were quantified using Il-6 Quantikine ELISA from R&D systems (Minneapolis, MN), with 50 μ l of cell culture media. two-way ANOVA with Dunnett's correction for multiple comparisons relative to DMSO control (n=3).

Gene Expression Analysis. RNA extractions from tissues were performed using the RNeasy Lipid Tissue Kit (Qiagen, Hilden, Germany). Whereas RNA extraction from cells utilized the RNeasy Kit, we used the Superscript First-Strand Synthesis System for reverse transcription–PCR (Invitrogen) with a 3:1 mixture of random hexamers/oligo dT primers for reverse transcription. Real-time PCR amplification was performed on samples in triplicate with Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) using the Applied Biosystems 7900HT Fast real-time PCR System and quantified using an internal standard curve and *Arbp* as the control gene. Statistical significance was determined by a two-way ANOVA with Dunnett’s correction for multiple comparisons relative to DMSO control (n=3).

Results

Synthesis of C-3 derivatives of amlexanox. We focused on simple modifications of the C-3 carboxylic acid function of amlexanox (**1**) (**Scheme 1**) to selected acid bioisosteres or ester and amide analogs in order to assess their effects on binding to our target enzymes and improving physicochemical properties and pharmacokinetics (PK). Treatment of **1** with thionyl chloride and catalytic DMF provided key acid chloride intermediate **2** onto which standard reaction conditions were applied to give the known ethyl ester **3** (84% yield) (Nohara et al., 1985), primary alcohol **4** (78% yield), and 5-amino-tetrazole amide **5a** (62% yield). Simpler amide derivatives were derived directly from amlexanox using standard coupling conditions (EDC, HOBT) to provide analogs **5b-d** in 40-48% isolated yields. The synthesis of a water-soluble ester derivative was best achieved through formation of the 1-imidazolyl ester of amlexanox, followed by reaction with 2-(dimethylamino)ethanol. Workup followed by hydrochloride salt formation provided **6** in 76% overall yield. To test

the effect on biological activity of swapping the 3-carboxylic acid function of amlexanox for a hydrogen, analog **7** was derived in 60% yield utilizing classical methodology for the decarboxylation of aromatic compounds (copper, refluxing quinolone).

The synthesis of elected C-3 carboxylic acid bioisosteres of amlexanox is delineated in **Scheme 2**. Toward this end, analogs **9**, **11**, and **12** were synthesized utilizing standard methodologies. Reaction of the commercially available C-3 nitrile of amlexanox (**8**) with sodium azide provided the known tetrazole **9** (Nohara et al., 1985) in 82% yield. Reaction of this with hydroxylamine afforded carboximidamide intermediate **10** from which ring closure reactions with triphosgene and triethylorthoformate provided the 1,2,4-oxadiazol-5(4*H*)-one **11** in 78% yield and 1,2,4-oxadiazole **12** in 62% yield, respectively. Compound structural assignments are supported by diagnostic peaks in the ¹H NMR spectra and by mass spectrometry.

The carboxylic acid on amlexanox enhances potency. Amlexanox displays an *in vitro* IC₅₀ of 0.8 ± 0.1 and 5.8 ± 0.8 μM towards TBK1 and IKKε, respectively (**Table 1**). Two analogs of amlexanox were synthesized in which the carboxylic acid was reduced to a primary alcohol (**4**) or removed (**7**). Reduction of the carboxyl in **4** decreased potency 30-fold whereas elimination of the carboxylic acid in **7** decreased potency 40-fold towards TBK1 (**Table 1**). Reduction of the carboxylate to a hydroxyl only modestly reduced potency towards IKKε, whereas elimination of the group enhanced potency two-fold. These data show that the carboxylic acid of amlexanox strongly influences the inhibition of TBK1, but less so in the case of IKKε.

Amide and ester derivatives reduce inhibition. Methyl (**5b**), 2-(diethylamino)ethyl (**5c**), and morpholine (**5d**) amide derivatives were synthesized to expand the SAR around the carboxylic acid moiety. Potency of **5c** and **5d** towards TBK1 was decreased by 45-fold and 90-fold, respectively. Similar decreases in potency were observed towards IKK ϵ . A selective loss in potency of more than 125-fold for TBK1 was observed for **5b**. IKK ϵ is however more tolerant to short modifications of the carboxylic acid in **5b** which only displays a three-fold reduction in potency. A pair of related ester analogs were next synthesized because they better mimic the parent carboxylic acid and thus might be less detrimental. An ester-linked 2-(dimethylamino)ethyl analog (**6**), similar to the amide-coupled amine **5c**, displayed a 5-fold decrease in potency but only towards TBK1. To test whether the length of the modification could underlie the observed decrease in potency, a short ethyl ester (**3**) analog was synthesized which decreased potency by more than 65-fold towards TBK1 and 10-fold towards IKK ϵ .

Carboxylic acid bioisosteres improve potency. Given the decrease in potency resulting from the elimination or derivatization of the carboxylic acid group, a series of bioisosteres was next investigated. Analogs of amlexanox containing tetrazole (**9**), oxadiazolone (**11**), or oxadiazole (**12**) groups in place of the carboxylic acid were synthesized. The tetrazole analog **9** displayed improved potency of 400 and 200 nM against TBK1 and IKK ϵ , respectively. Despite reduced solubility (**Table 2**), installation of an oxadiazolone moiety (**11**) improved potency to 1.6 ± 0.7 μ M towards IKK ϵ but reduced potency towards TBK1 to 2.9 ± 1.0 μ M, consistent with IKK ϵ being able to accept a wider variety of C-3 modifications. The oxadiazole analog **12** was essentially inactive against both TBK1 and IKK ϵ , likely due to its extremely poor aqueous solubility (**Table 2**).

Given the significant enhancement in potency of the tetrazole analog, an analog bearing a tetrazole attached to the core of amlexanox through an amide linkage, **5a**, was synthesized. **5a** reduced potency three-fold towards TBK1 but improved potency by three-fold towards IKK ϵ .

Amlexanox binds along the hinge of TBK1. In parallel with the above studies, an atomic structure of amlexanox in complex with TBK1 was determined in order to help interpret results and to guide future SAR. Initial efforts to obtain a co-crystal structure with the better-expressing but inactive TBK1-K38A yielded no crystals, but differential scanning fluorometry (DSF) with wild-type (WT) and TBK1-K38A revealed that the WT protein was stabilized whereas the K38A variant was destabilized by amlexanox (**Figure 1A, Supplemental Figure 1**). Subsequently, the WT TBK1·amlexanox crystal structure was determined to 3.65 Å spacings (PDB 5W5V, **Figure 1B, Supplemental Table 1**) (Data Supplement). The structure features strong density for amlexanox binding along the hinge of the kinase domain, mimicking the interactions made by the adenine ring of ATP. The binding mode is similar to that observed in the G protein-coupled receptor kinase 1·amlexanox complex (Homan *et al.*, 2014).

The amine forms a hydrogen bond with the backbone carbonyl of Glu87 whereas the pyridine nitrogen interacts with the backbone nitrogen of Cys87. The side chain of Leu15 in the beginning of the phosphate-binding loop (P-loop) packs against the tricyclic core of the drug. The carboxylic acid on amlexanox is 4.1 Å away from the hydroxyl of Thr156 and thus, considering the low resolution, either forms a weak hydrogen bond or favorable electrostatic interactions. Indeed, the TBK1-T156A variant displays a decrease in amlexanox. Interestingly, amlexanox displays slight increased in potency toward IKK ϵ -T156A (**Table 2**). No electron density is observed for the side chain of Lys38, which was required for obtaining the co-crystal

structure, indicating a high degree of mobility. Regardless, the Lys38 side chain would complement the negative charge of the carboxylate of amlexanox and, together with Thr156, help stabilize the compound in the active site.

Co-crystal structures of amlexanox C-3 derivatives. To investigate the molecular basis for the loss in potency observed for **3** and **5b**, the crystal structure of TBK1 in complex with the ethyl ester analog **3** was determined to 3.2 Å spacings (PDB 6BOD) (Data Supplement). Weak ligand density is observed, consistent with its higher 55 μM IC₅₀ value, but the planar density is situated along the hinge of the kinase domain similarly to the parent compound amlexanox (**Figure 2A**). A shift of the P-loop and neighboring strand (residues 37-42) in the N-terminal lobe of the kinase domain is also observed, resulting in a more open active site (**Figure 2B**). Compared to the TBK1·amlexanox structure, additional density is observed for residues 160-163 adjacent to the DFG motif of the kinase domain. Thus, it seems that steric clashes introduced by the addition of an ethyl group induce a twisting motion of the N-lobe of the kinase domain that leads to a more open kinase conformation.

To investigate the binding mode of the tetrazole analog **9**, its co-crystal structure was solved at 3.34 Å spacings (PDB 6BNY) (Data Supplement). The compound once again binds similarly to amlexanox (**Figure 2C**). Compared to the structure with **3**, the kinase domain of TBK1 adopts a more closed conformation. Unlike amlexanox, which forms a relatively long hydrogen bond with Thr156, the side chain of Thr156 rotates to accommodate the tetrazole ring, which allows a 3.2 Å hydrogen bond to form between the sulfur of the gatekeeper residue Met86 and the tetrazole moiety. The TBK1 variant M86L, another common gatekeeper residue in Ser/Thr kinases, did not express in insect cells but **9** displayed an increase in potency toward

IKK ϵ M86L (**Table 2**). The related compound **11** displays increased potency toward IKK ϵ M86L. Additionally, **9** and **11** display higher potencies against both TBK1 T156A and IKK ϵ T156A (**Table 2**). A simple explanation for the enhanced potencies of these analogs towards these mutants is a general reduction of steric clashes with either Met86 or Thr156 that allows for improved packing of the cyclic bioisosteres.

Because other amide derivatives were significantly less potent than amlexanox, the molecular basis for the retained potency of **5a** was independently assessed. The 3.6 Å co-crystal structure with TBK1 (PDB 6BOE) (Data Supplement) indicates that the core of the molecule again binds along the hinge (**Figure 2D**). Weak positive $|F_o| - |F_c|$ omit map density is observed for the amide linker and terminal tetrazole ring. The amide arm assumes a *cis* conformation relative to the amide bond and core of the inhibitor, and packs between Met142 and Val23. Residues 18-21 in the P-loop are disordered, disrupting P-loop crystal contacts observed in the other reported TBK1 structures and possibly accounting for the decreased resolution of the diffraction data. The loss in carboxylate interactions with Thr156 and Lys38 and disordering of the P-loop turn may partially be compensated for by favorable packing of the planar tetrazole ring under the ordered portion of the P-loop.

Bioisostere analogs display limited efficacy in cells. To determine whether carboxylic acid modifications improve cellular efficacy, 3T3-L1 adipocytes were treated with the highest-potency tetrazole analog (**9**) and the related oxadiazolone bioisostere (**11**). TBK1 mediates negative feedback regulation of AMP-activated protein kinase (AMPK) whereas IKK ϵ , and to a lesser extent TBK1, directly activate phosphodiesterase 3B and thereby reduce intracellular cAMP levels to attenuate catecholamine-stimulated adrenergic receptor signaling. Thus,

inhibition of both kinases produces a unique readout consisting of increased TBK1 phosphorylation at Ser172 as a consequence of the AMPK mediated negative feedback loop (Zhao *et al.*, 2018; Reilly *et al.*, 2013; Clark *et al.*, 2009), and phosphorylation and activation of p38 MAPK (Reilly *et al.*, 2015), and production of IL-6 (Reilly *et al.*, 2015) downstream of cAMP signaling. Treatment of adipocytes with **9** or **11** simultaneously stimulated TBK1 and p38 phosphorylation in a dose-dependent manner (**Figure 3A**). However, neither **9** nor **11** significantly increased pTBK1 response compared to amlexanox. Furthermore, although **11** more potently induces p38 phosphorylation, the maximum response is not greater than amlexanox. Compound **9** was worse than amlexanox at stimulating p38 phosphorylation, likely as a result of decreased permeability, assessed by cLogP (**Table 1**), and poor compound solubility in the assay medium (**Table 2**). Adipocytes treated with amlexanox or **11** display significantly increased *Il6* expression (**Figure 3B**). In agreement with previous studies, induction of *Il6* is blocked by pretreatment with the p38 MAPK inhibitor SB203580, confirming that the observed response to **11** is through activation of p38 (Barancík *et al.*, 2001; Reilly *et al.*, 2015). The tetrazole analog **9** did not induce *Il6* gene expression. Secretion of IL-6 from treated adipocytes was also assessed by ELISA (**Figure 3C**). In line with *Il6* expression, only treatment with analog **11** resulted in a significant increase in IL-6 secretion, though the increase was less robust than that produced by amlexanox.

Discussion

Amlexanox shows promise as a therapeutic lead for the treatment of obesity and type 2 diabetes via inhibition of kinases that are effectors of chronic low-grade inflammation in hepatic and adipose tissues. Initial characterization showed inhibition by amlexanox to be through an ATP-competitive mechanism, however the precise binding mode and molecular interactions leading to

inhibition were unknown (Reilly, *et al.*, 2013). The structure of TBK1 bound to amlexanox reveals a canonical type I ATP-competitive binding along the hinge of the kinase in the space occupied by the adenine ring of ATP. Compared to previously reported TBK1 structures in complex with the nanomolar inhibitors BX795 and MRT67307 (Ma *et al.*, 2012; Tu *et al.*, 2013; Larabi *et al.*, 2013), the small lobe of the kinase domain appears less ordered when in complex with amlexanox, particularly residues 15-19 in the P-loop. This finding is not unexpected because amlexanox is a lower potency inhibitor and occupies only the region along the hinge, whereas the more extended BX795 and MRT67307 inhibitors also pack under the P-loop.

The interaction between the carboxylate on amlexanox and the side chain hydroxyl of Thr156 amine is important for the inhibition of TBK1, but less so in the context of IKK ϵ where removal of the carboxylic acid moiety in **7** or introduction of the T156A mutation instead significantly improves potency. Reduction of the carboxylic acid to a primary alcohol in **4** also only perturbs inhibition of TBK1. As TBK1 and IKK ϵ are >70% identical in their kinase domains, the improved potency exhibited towards IKK ϵ by **7** and **5b** is surprising. One notable difference between the two kinases lies at position 90 in the hinge, which corresponds to a proline in TBK1 and a serine in IKK ϵ . The presence of a proline in the hinge of TBK1 may restrict the relative orientation of its kinase domain lobes. Thus, decreased potency may selectively occur in TBK1 because it is less able to reconfigure itself and optimally interact with inhibitors lacking a carboxylate. Verification of this model will have to await determination of atomic structures of IKK ϵ . Disruption of the carboxylate-Thr156 interaction seems however to be a viable strategy for improving selectivity, and often potency, toward IKK ϵ .

All amide and ester modifications of the carboxylic acid of amlexanox decreased potency toward TBK1, whereas only **5d** significantly decreased potency toward IKK ϵ . Given the effect of

TBK1- and IKK ϵ -T156A on amlexanox potency, the trend may simply arise from disruption of the carboxylate-Thr156 hydroxyl interaction. Extensions to the carboxylic acid that introduce steric clashes in TBK1 that further impede ligand binding. Indeed, the co-crystal structure of TBK1 bound to **3** reveals that esterification of amlexanox does not change the binding position of the core of the inhibitor along the kinase hinge, but leads to a twist in the P-loop and a more open conformation of the kinase domain which may stem from clashes between the ethyl modification and the kinase DFG motif and P-loop. Interestingly, the amide- and ester-coupled amines **5c** and **6**, respectively, and the short methyl amide **5b**, display no significant reduction in potency towards IKK ϵ , possibly as a result of increased hinge flexibility in this enzyme relative to TBK1. The coupling of a 5-membered tetrazole ring through an amide linkage in **5a** improves IKK ϵ inhibition but only exhibits a modest decrease in potency towards TBK1, whereas the 6-membered 2-morpholinoethyl analog **5d** is a poor inhibitor of both kinases. These results further suggest that there is a steric size limit for packing under the P-loop. Indeed, other potent but promiscuous TBK1 and IKK ϵ inhibitors such as BX795 and MRT67307 pack 4- and 5-membered cyclobutyl and thiophene rings under the P-loop (Ma *et al.*, 2012; Tu *et al.*, 2013; Larabi *et al.*, 2013).

The gatekeeper residue in kinases plays a key role in the formation of hydrophobic spines that must form for the kinase to assume an active conformation (Taylor *et al.*, 2011). Therefore, Met86 was mutated to leucine, another common Ser/Thr kinase gatekeeper residue, in order to minimally perturb kinase activity and conformation. Surprisingly, the M86L variant of TBK1 did not express whereas IKK ϵ M86L displays increased potency toward amlexanox (**1**), **9**, and **11** despite the loss of hydrogen bonding between Met86 and the tetrazole ring of **9** and no interactions between Met86 and amlexanox. Because amlexanox and analogs thereof are type I

inhibitors which favor binding to the active conformation of kinases, it is possible that M86L better stabilizes the kinase hydrophobic spine leading to a more active kinase conformation and improved potencies or simply enlarged the binding pocket such that the bulkier acid bioisosteres are better accommodated.

Because TBK1 and IKK ϵ play different roles in chronic inflammation associated with obesity (Chiang *et al.*, 2009; Zhang *et al.*, 2018), the development of inhibitors selective for either kinase would enable pharmacological interrogation of the signaling pathways associated with each enzyme. The SAR around the carboxylic acid moiety of amlexanox reveals that IKK ϵ is more tolerant to modifications at the C-3 position. Simple decarboxylation of amlexanox (**7**) improves selectivity toward IKK ϵ by more than one order of magnitude. Other modifications, such as conversion of the carboxylic acid to a methyl amide (**5b**), also improve selectivity towards IKK ϵ . Coupled with modifications at other positions, such as the C-7 isopropyl, these and related carboxylic acid derivatives represent possible routes to the generation of IKK ϵ -selective inhibitors.

The lack of improved cellular activity observed for the tetrazole analog of amlexanox is not surprising, as tetrazole modifications have been reported to decrease cellular permeability (**Table 1**) (Lassalas *et al.*, 2016). Despite a decrease in potency toward TBK1 and solubility (**Table 2**), the oxadiazolone analog **11** produces a significant cellular response, albeit less than amlexanox, perhaps due to increased cellular permeability (cLogP) of oxadiazolones compared to carboxylic acids (**Table 1**) (Lassalas *et al.*, 2016). Because amlexanox and related analogs are type I kinase inhibitors with a general ATP-competitive mechanism, we cannot exclude the possibility of off-target effects, especially given the indirect nature of measuring p-TBK1, p-p38 MAPK, and IL-6. However, this particular combination of readouts has been extensively

validated in the context of amlexanox (Reilly *et al.*, 2013, Reilly *et al.*, 2015, Zhao *et al.*, 2018). Given the modest nature of the C-3 modifications and observed effects in all three readouts, analogs **9** and **11** are likely on-target, at least in the context of cultured adipocytes. The selectivity of analogs exhibiting more promising cellular efficacy should be thoroughly assessed prior to studies *in vivo* to predict and minimize deleterious off-target effects stemming from inhibition of kinases prevalent in other cell types.

Because free carboxylic acid groups are prone to glucuronidation during phase II metabolism (Sakaguchi *et al.*, 2004), installation of less acidic bioisosteres may improve metabolic properties of amlexanox. However, in assays with cultured adipocytes metabolism is expected to be insignificant due to a lack of hepatic drug metabolizing enzymes. Difficulties solubilizing **9** and **11** (**Table 2**) prohibited testing in obese mice and highlights another PK property that may be improved through the installation of alternative bioisosteres. The co-crystal structure with the tetrazole analog **9** will serve as a guide towards identifying alternative bioisosteres that maintain or improve potency while also improving cellular response. In particular, the related thiadiazolone and isoxazole bioisosteres are predicted to be significantly more cell permeable and are options for future exploration (Vitaku *et al.*, 2014; Lassalas *et al.*, 2016).

Acknowledgments

The authors would like to thank David Ginsburg (University of Michigan) for use of his qPCR instrument used for thermal shift experiments.

Authorship Contributions

Participated in research design: Beyett, Gan, Reilly, Chang, Showalter, Saltiel, Tesmer

Conducted experiments: Beyett, Gan, Reilly, Chang, Gomez

Contributed new reagents of analytic tools: Gan

Performed data analysis: Beyett, Gan, Reilly, Chang, Gomez, Showalter, Saltiel, Tesmer

Wrote or contributed to the writing of the manuscript: Beyett, Gan, Showalter, Saltiel, Tesmer

References

- Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung L-W, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, and Zwart PH (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**:213–221.
- Barancik M, Boháčová V, Kvacajová J, Hudecová S, Krizanová O, and Breier A (2001) SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. *Eur J Pharm Sci* **14**:29–36.
- Bell J (2005) Amlexanox for the Treatment of Recurrent Aphthous Ulcers. *Clin Drug Investig* **25**:555–566.
- Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, and Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* **66**:12–21.
- Chiang S-H, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, Ma J-T, Zhou J, Qi N, Westcott D, Delproposto JB, Blackwell TS, Yull FE, and Saltiel AR (2009) The protein kinase IKKepsilon regulates energy balance in obese mice. *Cell* **138**:961–975.
- Clark K, Peggie M, Plater L, Sorcek RJ, Young ERR, Madwed JB, Hough J, McIver EG, and Cohen P (2011) Novel cross-talk within the IKK family controls innate immunity. *Biochem J* **434**:93–104.
- Clark K, Plater L, Peggie M, and Cohen P (2009) Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. *J Biol Chem* **284**:14136–

14146.

Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010) Features and development of Coot.

Acta Crystallogr D Biol Crystallogr **66**:486–501.

Homan K, Wu E, Cannavo A, Koch W, and Tesmer J (2014) Identification and Characterization of Amlexanox as a G Protein-Coupled Receptor Kinase 5 Inhibitor. *Molecules* **19**:16937–16949.

Kabsch W (2010) XDS. *Acta Crystallogr D Biol Crystallogr* **66**:125–132.

Larabi A, Devos JM, Ng S-L, Nanao MH, Round A, Maniatis T, and Panne D (2013) Crystal structure and mechanism of activation of TANK-binding kinase 1. *Cell Rep* **3**:734–746.

Lassalas P, Gay B, Lasfargeas C, James MJ, Tran V, Vijayendran KG, Brunden KR, Kozlowski MC, Thomas CJ, Smith AB, Huryn DM, and Ballatore C (2016) Structure Property Relationships of Carboxylic Acid Isosteres. *J Med Chem* **59**:3183–3203.

Ma X, Helgason E, Phung QT, Quan CL, Iyer RS, Lee MW, Bowman KK, Starovasnik MA, and Dueber EC (2012) Molecular basis of Tank-binding kinase 1 activation by transautophosphorylation. *Proc Natl Acad Sci USA* **109**:9378–9383.

Makino H, Saijo T, Ashida Y, Kuriki H, and Maki Y (1987) Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. *Int Arch Allergy Appl Immunol* **82**:66–71.

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. *J Appl Crystallogr* **40**:658–674.

Moriarty NW, Grosse-Kunstleve RW, and Adams PD (2009) electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation.

Acta Crystallogr D Biol Crystallogr **65**:1074–1080.

Morin A, Eisenbraun B, Key J, Sanschagrín PC, Timony MA, Ottaviano M, and Sliz P (2013)

Collaboration gets the most out of software. *Elife* **2**:e01456.

Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang S-H, Chang L, and Saltiel AR (2013)

Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKK ϵ and TBK1. *Elife* **2**:e01119.

Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, Chenevert TL, Korytnaya E,

Neidert AH, Hench R, Rus D, Horowitz JF, Poirier B, Zhao P, Lehmann K, Jain M, Yu R, Liddle C, Ahmadian M, Downes M, Evans RM, and Saltiel AR (2017) Inhibition of IKK ϵ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. *Cell Metab* **26**:157–170.

Reilly SM, and Saltiel AR (2017) Adapting to Obesity with Adipose Tissue Inflammation. *Nat Rev Endo* **13** (11), 633–643.

Reilly SM, Ahmadian M, Zamarron BF, Chang L, Uhm M, Poirier B, Peng X, Krause DM,

Korytnaya E, Neidert A, Liddle C, Yu RT, Lumeng CN, Oral EA, Downes M, Evans RM, and Saltiel AR (2015) A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesis. *Nat Commun* **6**:6047.

Reilly SM, Chiang S-H, Decker SJ, Chang L, Uhm M, Larsen MJ, Rubin JR, Mowers J, White

NM, Hochberg I, Downes M, Yu RT, Liddle C, Evans RM, Oh D, Li P, Olefsky JM, and Saltiel AR (2013) An inhibitor of the protein kinases TBK1 and IKK ϵ improves obesity-related metabolic dysfunctions in mice. *Nat Med* **19**:313–321.

Sakaguchi K, Green M, Stock N, Reger TS, Zunic J, and King C (2004) Glucuronidation of

carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. *Archives*

of Biochem and Biophys **424**:219–225.

Saltiel AR (2016) New therapeutic approaches for the treatment of obesity. *Sci Transl Med* **8**:323rv2.

Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, and Gortmaker SL (2011) The global obesity pandemic: shaped by global drivers and local environments. *Lancet* **378**:804–814.

Taylor SS, and Kornev AP (2011) Protein kinases: evolution of dynamic regulatory proteins. *Trends Biochem Sci* **36**:65–77.

Tu D, Zhu Z, Zhou AY, Yun C-H, Lee K-E, Toms AV, Li Y, Dunn GP, Chan E, Thai T, Yang S, Ficarro SB, Marto JA, Jeon H, Hahn WC, Barbie DA, and Eck MJ (2013) Structure and ubiquitination-dependent activation of TANK-binding kinase 1. *Cell Rep* **3**:747–758.

Vitaku, E.; Smith, D. T.; Njardarson, J. T. (2014) Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles Among U.S. FDA Approved Pharmaceuticals. *J Med Chem*, **57**:24, 10257–10274.

Zhao P, Wong K, Sun X, Reilly SM, Uhm M, Liao Z, Skorobogatko Y, Saltiel AR (2018) TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. *Cell* **172**:731-743.

Footnotes

This study was supported by National Institutes of Health (NIH) Pharmacological Sciences Training Program fellowship [T32-GM007767] and U.S. Department of Education GAANN fellowship [P200A150164] to TSB, as well as NIH R01 [grants HL122416, HL071818, DK100319, DK060591, DK60597], K01 [grant DK105075], and P30 [grant DK06349]. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357, and the use of LS-CAT Sector 21 was supported by the Michigan Economic Development Corporation and Michigan Technology Tri-Corridor [grant 085P1000817].

Legends for Figures

Figure 1 Structural analysis of the TBK1·amlexanox complex. **A)** Amlexanox (200 μ M) only stabilizes the wild-type (WT) form of TBK1, as indicated by a positive shift in the melting temperature T_m (average \pm SEM, $n=2$, two-way ANOVA with Bonferroni correction for multiple comparisons to - amlexanox sample, $**p\leq 0.01$, $***p\leq 0.001$). **B)** TBK1·amlexanox crystal structure at 3.65 Å. Amlexanox (**1**) binds along the kinase hinge and forms specific interactions with the backbone of Glu87 and Cys89 and the side chain of Thr156. Mesh represents positive $|F_o| - |F_c|$ density contoured at 3.0σ .

Figure 2 Structural analysis of TBK1 in complex with carboxylic acid analogs of amlexanox. **A)** TBK1·**3** crystal structure at 3.2 Å. Mesh represents positive $|F_o| - |F_c|$ omit map density contoured at 2.0σ . **B)** Alignment of the TBK1·**3** (green) with TBK1·amlexanox (gray) complexes. The marked rotation in the P-loop is indicated by spheres at the $C\alpha$ positions of Thr20 and Val39. **C)** TBK1·**9** crystal structure at 3.3 Å with mesh representing 3.0σ positive $|F_o| - |F_c|$ omit density. **D)** TBK1·**5a** crystal structure at 3.6 Å with mesh representing 3.0σ positive $|F_o| - |F_c|$ omit density. Dashed black lines correspond to hydrogen bonds with corresponding distances indicated.


Figure 3 Adipocyte cellular responses upon treatment with amlexanox (**1**) and selected analogs. **A)** Western blot for phosphorylation of TBK1 and p38 MAPK after incubation of 3T3-L1 adipocytes with 2-50 μ M amlexanox (**1**), **9**, or **11** for 1 h. Quantified results for pTBK1 and p-p38 are displayed below the blot (average \pm SD, $n=2$ technical replicates, $**p\leq 0.01$, $***p\leq 0.001$, two-way ANOVA with Dunnett's correction for multiple comparisons relative to amlexanox). **B)**

Expression of *Il6* as determined by qPCR in 3T3-L1 adipocytes treated with 50 μ M compound for 4 h. Expression was quantified with and without pretreatment with the p38 MAPK inhibitor SB203580 (average \pm SD, n=3 biological replicates, two-way ANOVA with Dunnett's correction for multiple comparisons relative to DMSO control, *** $p \leq 0.001$). C) Secreted Il-6 from 3T3-L1 adipocytes treated with 50 μ M compound for 4 h as determined by ELISA (average \pm SD, n=2 technical replicates, two-way ANOVA with Dunnett's correction for multiple comparisons relative to DMSO control, ** $p \leq 0.01$, *** $p \leq 0.001$).

Scheme 1. Reagents and conditions: (a) SOCl_2 / cat. DMF, DCM, reflux, 4 h, $\sim 100\%$. (b) EtOH, reflux, 1h, 84%. (c) 4 eq. NaBH_4 , THF, RT, 1.5 h, 78%. (d) for **5a**: 5-aminotetrazole, pyridine, RT, 7h, 62%. (e) for **5b-d**: RNH_2 , EDC·HCl, HOBt, DIEA, DMF, RT, 16 h, 40-48%. (f) CDI, 2-(dimethylamino)ethanol, DMF, 60 °C, 22 h, 89%; ethereal HCl, DCM, RT, 85%. (g) cat. Cu metal, quinolone, reflux, 60%. See supplemental methods for full names of solvent and reagent abbreviations.

Scheme 2. Reagents and conditions: (a) NaN_3 , NH_4Cl , DMF, 90 °C, 16 h, 82%. (b) $\text{NH}_2\text{OH}\cdot\text{HCl}$, aq. NaHCO_3 , EtOH, reflux, 92%. (c) triphosgene, *p*-dioxane, 100°C, 4 h, then H_2O , 78%. (d) $(\text{EtO})_3\text{CH}$, cat. $\text{BF}_3\cdot\text{Et}_2\text{O}$, 80 °C, 1h, 62%. See supplemental methods for full names of solvent and reagent abbreviations.


Table 1



Compound #	R	^a cLogP	^b TBK1 IC ₅₀ (μM)	^b IKKε IC ₅₀ (μM)	^c Selectivity for IKKε
1 (Amlexanox)	-COOH	3.65	0.8 ± 0.1	5.8 ± 0.8	0.2
3	-COOEt	4.36	55 ± 29***	65 ± 47***	0.8
4	-CH ₂ OH	2.58	24 ± 5.7***	18 ± 8.2	1.3
5a		3.43	2.9 ± 0.5	1.6 ± 0.4	1.8
5b		3.07	>100***	17 ± 13	>5.9
5c		3.80	36 ± 14***	14 ± 8.6	2.6
5d		2.87	73 ± 26***	57 ± 23***	1.3
6		4.02	4.5 ± 0.8**	5.4 ± 2.0	0.8
7	-H	3.35	33 ± 18***	2.6 ± 1.1	13
9		3.22	0.4 ± 0.05	0.2 ± 0.03***	2.0
11		3.04	2.9 ± 1.0	1.6 ± 0.7	1.8
12		3.39	>100***	>100***	1

^aCalculated partitioning coefficient (calculated via Marvin, ChemAxon). Larger values suggest enhanced cellular permeability. ^b*In vitro* potency (IC₅₀) towards TBK1 and IKKε (n=3, mean ± SEM). Statistical significance from amlexanox determined by two-way ANOVA with Dunnett's multiple comparison correction, *p≤0.05, **p≤0.01, ***p≤0.001. ^cSelectivity determined by dividing mean TBK1 IC₅₀ by the mean IKKε IC₅₀.

Table 2



Compound #	1 (Amlexanox)	9	11	12
R	-COOH			
^a Solubility (mg mL ⁻¹)	≥20	≥2.5	<1	<<0.5
IC₅₀ (μM)^b				
TBK1	0.8 ± 0.1	0.4 ± 0.05	2.9 ± 1.0	>100
TBK1 T156A	10 ± 1.5***	0.06 ± 0.06	1.9 ± 1.4	n.i.
IKKε	5.8 ± 0.8	0.2 ± 0.03	1.6 ± 0.7	>100
IKKε M86L	1.1 ± 1.0***	0.03 ± 0.02	0.04 ± 0.03*	n.i.
IKKε T156A	1.9 ± 1.4***	0.02 ± 0.01	0.3 ± 0.2*	n.i.

^aThermodynamic solubility determined by first dissolving each compound at a basic pH (dilute NaOH solution) and adjusting to pH 7.4-7.6 with buffer. ^b*In vitro* potency (IC₅₀, μM) towards TBK1 and IKKε variants (mean ± SEM, n=3). TBK1 M86L did not express in insect cells. Statistical significance relative to WT variant determined via two-way ANOVA with Bonferroni correction for multiple comparisons (*p<0.05, ***p<0.001). n.i. no inhibition up to 200 μM.

Figure 1




Figure 2







Figure 3



Scheme 1



Scheme 2



Supplemental Data – *Molecular Pharmacology*

**Carboxylic acid derivatives of amlexanox display enhanced potency towards
TBK1 and IKK ϵ and reveal mechanisms for selective inhibition**

Tyler S. Beyett, Xinmin Gan, Shannon M. Reilly, Louise Chang, Andrew V. Gomez, Alan R.
Saltiel, Hollis D. Showalter, and John J. G. Tesmer


Program in Chemical Biology (T.S.B.), Life Sciences Institute (T.S.B., L.C., and J.J.G.T.),
Departments of Medicinal Chemistry (X.G., H.D.S., J.J.G.T.), Pharmacology (J.J.G.T.),
Biological Chemistry (J.J.G.T.), and Vahlteich Medicinal Chemistry Core, College of Pharmacy
(X.G. and H.D.S.), University of Michigan, Ann Arbor, Michigan. Institute for Diabetes and
Metabolic Health (S.M.R., A.V.G., and A.R.S.), Departments of Medicine (S.M.R. and A.R.S.),
and Pharmacology (A.V.G. and A.R.S.), University of California, San Diego, La Jolla,
California.

Supplemental Table 1. TBK1 crystallographic data collection and refinement statistics

Ligand (PDB entry)	Amlexanox (5W5V)	9 (6BNY)	3 (6BOD)	5a (6BOE)
Wavelength (Å)	0.97857	0.97872	0.97857	1.03312
Resolution range	39.2 - 3.65 (3.78 - 3.65)*	44.1 - 3.34 (3.46 - 3.34)*	40.0 - 3.20 (3.31 - 3.20)*	35.4 - 3.60 (3.73 - 3.60)*
Space group	<i>P</i> 3 ₂ 2 1	<i>P</i> 3 ₂ 2 1	<i>P</i> 3 ₂ 2 1	<i>P</i> 3 ₂ 2 1
Unit cell constants (Å, °)	135.0 135.0 84.9 90 90 120	134.8 134.8 85.3 90 90 120	134.3 134.3 85.3 90 90 120	134.5 134.5 85.5 90 90 120
Total reflections	76280 (6549)	145201 (13401)	245551 (24305)	201857 (20642)
Unique reflections	10120 (923)	13238 (1305)	14970 (1463)	10626 (1055)
Multiplicity	7.5 (7.1)	11.0 (10.3)	16.4 (16.6)	19.0 (19.5)
Completeness (%)	98.0 (90.6)	99.5 (96.2)	99.6 (99.3)	99.5 (98.7)
Mean I/σ(I)	12.60 (1.09)	16.24 (1.63)	18.17 (1.60)	16.37 (1.25)
Wilson B-factor	166.0	112.4	121.9	166.0
R_{meas}	0.102 (2.23)	0.143 (1.66)	0.113 (2.14)	0.145 (1.91)
CC_{1/2}	0.999 (0.403)	0.999 (0.599)	1 (0.548)	1 (0.553)
Reflections used in refinement	10087 (907)	13206 (1277)	14926 (1458)	10592 (1050)
Reflections used for R_{free}	1011 (91)	1321 (127)	1495 (145)	1061 (105)
R_{work}	0.229 (0.350)	0.227 (0.352)	0.223 (0.412)	0.244 (0.428)
R_{free}	0.290 (0.371)	0.286 (0.382)	0.271 (0.454)	0.267 (0.416)
Non-hydrogen atoms (#)	4887	4956	4960	4895
Protein	4865	4932	4936	4868
Ligand	22	24	24	27
RMSD bonds (Å)	0.003	0.002	0.002	0.002
RMSD angles (°)	0.77	0.50	0.41	0.41
Ramachandran favored (%)	98.6	91.0	96.3	95.6
Ramachandran allowed (%)	1.4	8.7	3.7	4.1
Ramachandran outliers (%)	0	0.3	0	0.3
Rotamer outliers (%)	0	0	0	0
Clashscore	7.0	6.9	4.2	5.1
Average B-factor	185	133	142	182
Protein	185	133	142	182
Ligand	158	97	184	187

*Statistics for the highest-resolution shell are shown in parentheses

Supplemental Figure 1: Differential scanning fluorimetry melting curves for TBK1 variants (n=3, average \pm SD). The decrease in fluorescence at temperatures greater than 45 °C is due to protein aggregation excluding the reporter dye.



Supplemental Synthetic Methods

Solvent and reagent abbreviations. Solvents: DCM (dichloromethane), DMSO (dimethylsulfoxide), DMF (*N,N*-dimethylformamide), EtOH (ethanol), H₂O (water), MeOH (mEtOH), THF (tetrahydrofuran). Reagents: CDI (1,1'-carbonyldiimidazole), HOBT (hydroxybenzotriazole), EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide), DIEA (diisopropylethylamine), HCl (hydrogen chloride). NaHCO₃ (sodium bicarbonate), Na₂CO₃ (sodium carbonate), NaOH (sodium hydroxide), NH₄Cl (ammonium chloride), NaN₃ (sodium azide).

2-Amino-7-isopropyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carbonyl chloride (2). Literature citation for methodology (Ren et al., 2012). To a stirred suspension of **1** (300 mg, 1 mmol) and DMF (8 mg, 0.11 mmol) in DCM (30 mL) was dropwise added thionyl chloride (15 mL, 206 mmol) and the resulting mixture was heated at reflux for 4 h. The mixture was concentrated *in vacuo* to afford **2** (325 mg, ~100%) as an orange solid, which was unstable to further purification and thus used directly in the next step. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.83 (s, 1H), 7.94 (d, *J* = 2.2 Hz, 1H), 7.77 (dd, *J* = 8.5, 2.2 Hz, 1H), 7.64 (d, *J* = 8.6 Hz, 1H), 3.06 (p, *J* = 7.2 Hz, 1H), 1.25 (d, *J* = 7.0 Hz, 6H).

Ethyl 2-amino-7-isopropyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carboxylate (3) (Nohara et al., 1985). Literature citation for methodology (Pfau et al., 2010). A suspension of **2** (15 mg, 0.05 mmol) in EtOH (1 mL) was heated at reflux for 1 h. The mixture was concentrated to yield **3** (13 mg, 84%) as a light orange solid. ¹H NMR (400 Mz, DMSO-*d*₆) δ 8.80 (s, 1H), 8.36 (s, 1H), 8.09 (s, 1H), 7.92 (d, *J* = 2.3 Hz, 1H), 7.74 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.53 (d, *J* = 8.6 Hz, 1H), 4.35 (q,

$J = 7.1$ Hz, 2H), 3.06 (p, $J = 6.9$ Hz, 1H), 1.36 (t, $J = 7.1$ Hz, 3H), 1.26 (d, $J = 6.9$ Hz, 6H). MS m/z 327.0 (M+H)⁺. HPLC 89%.

2-Amino-3-(hydroxymethyl)-7-isopropyl-5H-chromeno[2,3-*b*]pyridin-5-one (4). Literature citation for methodology (Gilligan et al., 2006). A suspension of **2** (150 mg, 0.47 mmol) in THF (20 mL) was treated with sodium borohydride (72 mg, 1.9 mmol) and the mixture was stirred for 1.5 h at room temperature. The mixture was quenched with H₂O and the resultant clear orange solution was stirred for 10 min and extracted with DCM (2x). The combined organic phases were dried and concentrated to a solid that was triturated in a small amount of DCM, collected, and dried to give **4** (105 mg, 78%) as a light orange solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.16 (s, 1H), 7.93 (d, $J = 2.3$ Hz, 1H), 7.69 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.51 (d, $J = 8.6$ Hz, 1H), 7.21 (br s, 2H), 5.37 (t, $J = 5.6$ Hz, 1H), 4.47 - 4.36 (m, 2H), 3.05 (p, $J = 6.9$ Hz, 1H), 1.26 (d, $J = 6.9$ Hz, 6H). MS m/z 285.1237 (M+H)⁺. HPLC 95%.

2-Amino-7-isopropyl-5-oxo-*N*-(1H-tetrazol-5-yl)-5H-chromeno[2,3-*b*]pyridine-3-carboxamide (5a). Literature citation for methodology (Bergmanis et al., 2003). To a solution of tetrazole-5-amine (36 mg, 0.43 mmol) in pyridine (1 mL) was slowly added **2** (45 mg, 0.14 mmol) at room temperature. The mixture was stirred for 7 h and then diluted with acetonitrile (10 mL). The resulting suspension was stirred for 1.5 h and the solids were collected, washed with acetonitrile, and dried to give **5a** (32 mg, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.11 (s, 1H), 8.27 (br s, 2H), 7.96 (d, $J = 2.2$ Hz, 1H), 7.73 (dd, $J = 8.6, 2.2$ Hz, 1H) 7.56 (d, $J = 8.6$ Hz, 1H), 3.07 (p, $J = 6.9$ Hz, 1H), 1.27 (d, $J = 6.9$ Hz, 6H). MS m/z 366.0 (M+H)⁺. HPLC 89%.

2-Amino-7-isopropyl-*N*-methyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carboxamide (5b).

Literature citation for methodology (Liang et al., 2008). A solution of amlexanox (**1**; 100 mg, 0.335 mmol), methylamine hydrochloride (34 mg, 0.50 mmol), EDC hydrochloride (96 mg, 0.50 mmol), HOBt (54 mg, 0.40 mmol), DIEA (130 mg, 1.0 mmol) and DMF (2 mL) was stirred at room temperature for 16 h. The precipitated solid was collected, washed with DMF (2 x 0.5 mL) and then dissolved in DCM. The solution was washed with saturated aqueous NaHCO₃, dried, and concentrated to afford **5b** (42 mg, 40%) as a white solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.85 (d, *J* = 4.9 Hz, 1H), 8.73 (s, 1H), 7.94 (d, *J* = 2.3 Hz, 1H), 7.73 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.53 (d, *J* = 8.6 Hz, 1H), 3.06 (p, *J* = 6.9 Hz, 1H), 2.77 (d, *J* = 4.4 Hz, 3H), 1.26 (d, *J* = 6.9 Hz, 6H). MS *m/z* 312.1 (M+H)⁺. HPLC 99%.

2-Amino-*N*-(2-(diethylamino)ethyl)-7-isopropyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carboxamide (5c). Similar reaction was carried out for amlexanox (**1**; 150 mg, 0.50 mmol), *N,N*-diethylethylenediamine (88 mg, 0.75 mmol), HOBt (82 mg, 0.60 mmol), EDC hydrochloride (144 mg, 0.75 mmol), DIEA (195 mg, 1.51 mmol), and DMF (3 mL). The mixture was distributed between H₂O and DCM, and the organic phase was dried and concentrated to a solid that was purified by silica gel flash chromatography (elution with 4-7% MeOH in DCM) to provide **5c** (95 mg, 48%) as a solid. ¹H NMR (400 MHz, chloroform-*d*) δ 8.70 (s, 1H), 8.09 (d, *J* = 2.3 Hz, 1H), 7.58 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.43 (d, *J* = 8.6 Hz, 1H), 7.38 (br s, 1H), 3.52 (q, *J* = 5.6 Hz, 2H), 3.04 (p, *J* = 6.9 Hz, 1H), 2.74 (t, *J* = 6.0 Hz, 2H), 2.66 (q, *J* = 7.1 Hz, 4H), 1.31 (d, *J* = 6.9 Hz, 6H), 1.12 (t, *J* = 7.1 Hz, 6H). MS *m/z* 397.1 (M+H)⁺. HPLC 96%.

2-Amino-7-isopropyl-N-(2-morpholinoethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-

carboxamide (5d). Similar reaction of amlexanox (**1**; 200 mg, 0.67 mmol), 4-(2-aminoethyl)morpholine (131 mg, 1.0 mmol), EDC hydrochloride (192 mg, 1.0 mmol), HOBt (109 mg, 0.81 mmol), DIEA (260 mg, 2.0 mmol) and DMF (4 mL) followed by workup and purification (elution with 3-5% MeOH in DCM) as described for **5c** above gave **5d** (123 mg, 45%) as solid. ¹H NMR (500 MHz, chloroform-*d*) δ 8.65 (s, 1H), 8.10 (d, *J* = 2.3 Hz, 1H), 7.59 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.44 (d, *J* = 8.5 Hz, 1H), 6.92 (br s, 1H), 3.77 (t, *J* = 4.6 Hz, 4H), 3.55 (q, *J* = 5.6 Hz, 2H), 3.05 (p, *J* = 6.9 Hz, 1H), 2.64 (t, *J* = 6.0 Hz, 2H), 2.54 (d, *J* = 4.7 Hz, 4H), 1.32 (d, *J* = 6.9 Hz, 6H). MS *m/z* 411.1 (M+H)⁺. HPLC 99%.

2-(Dimethylamino)ethyl 2-amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-

carboxylate, hydrochloride (6). Literature citation for methodology (Kimura et al., 2007). A mixture of amlexanox (**1**; 200 mg, 0.67 mmol), CDI (130 mg, 0.81 mmol) and DMF (5.0 mL) was stirred at room temperature for 30 min. The solution was then treated with 2-(dimethylamino)ethanol (71.7 mg, 0.81 mmol) and stirred at 60 °C for 22 h. After cooling to room temperature the mixture was added to H₂O (65 mL) and stirred at room temperature for 5 h. The precipitated white solid was collected, washed with H₂O and dried at 60 °C *in vacuo* to afford the free base of **6** (220 mg, 89%). ¹H NMR (400 MHz, chloroform-*d*) δ 9.15 (s, 1H), 8.32 (br s, 1H), 8.10 (d, *J* = 2.3 Hz, 1H), 7.58 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.43 (d, *J* = 8.5 Hz, 1H), 5.88 (br s, 1H), 4.46 (t, *J* = 5.9 Hz, 2H), 3.04 (p, *J* = 7.0 Hz, 1H), 2.77 (t, *J* = 5.9 Hz, 2H), 2.37 (s, 6H), 1.31 (d, *J* = 6.9 Hz, 6H). MS *m/z* 370.2 (M+H)⁺. To a stirred solution of the free base (218 mg, 0.59 mmol) in DCM (5 mL) was added HCl in diethyl ether (1 M; 1.77 mL). The suspension was stirred for 2 min and concentrated. The residue was triturated in ether, collected, and dried to

give **6** hydrochloride (203 mg, 85%). ^1H NMR (400 MHz, DMSO- d_6) δ 10.44 (br s, 1H), 8.93 (s, 1H), 8.43 (br s, 1H), 8.07 (br s, 1H), 7.92 (d, $J = 2.3$ Hz, 1H), 7.75 (dd, $J = 8.7, 2.3$ Hz, 1H), 7.55 (d, $J = 8.6$ Hz, 1H), 4.65 (t, $J = 5.0$ Hz, 2H), 3.57 (m, 2H), 3.06 (p, $J = 6.9$ Hz, 1H), 2.87 (d, $J = 2.4$ Hz, 6H), 1.26 (d, $J = 6.9$ Hz, 6H). MS m/z 370.2 (M+H) $^+$. HPLC 97%.

2-Amino-7-isopropyl-5H-chromeno[2,3-b]pyridin-5-one (7). Literature citation for methodology (Eastwood et al., 2010). A mixture of amlexanox (**1**; 300 mg, 1.0 mmol) and copper powder (64 mg, 1.0 mmol) in quinoline (5 mL) was heated at reflux for 1.5 h utilizing a heating mantle brought to 260 °C. After cooling to room temperature, the solution was diluted with 250 mL of hexanes and the resulting mixture was stirred at room temperature for 1.5 h. The top layer was carefully decanted and the remaining black sticky oil was washed with hexanes (3x) and diluted with DCM. The resulting suspension was washed successively with 5% aqueous Na_2CO_3 (40 mL) and then 1N aqueous NaOH (10 mL). The DCM phase was filtered through a pad of Celite, dried, and concentrated to a dark grey solid that was dissolved in DCM and purified by silica gel flash chromatography (elution with 2% MeOH in DCM) to give **7** (154 mg, 60%) as a solid. ^1H NMR (400 MHz, chloroform- d) δ 8.42 (d, $J = 8.5$ Hz, 1H), 8.12 (d, $J = 2.3$ Hz, 1H), 7.58 (dd, $J = 8.6, 2.3$ Hz, 1H), 7.45 (d, $J = 8.6$ Hz, 1H), 6.54 (d, $J = 8.5$ Hz, 1H), 5.19 (s, 2H), 3.05 (p, $J = 6.9$ Hz, 1H), 1.31 (d, $J = 6.9$ Hz, 6H). MS m/z 255.0 (M+H) $^+$. HPLC 95%.

2-Amino-7-isopropyl-3-(1H-tetrazol-5-yl)-5H-chromeno[2,3-b]pyridin-5-one (9). Compound **9** was made by a slight modification of a literature procedure (Nohara et al., 1985): A mixture of 2-amino-7-isopropyl-5-oxo-5H-chromeno[2,3-b]pyridine-3-carbonitrile (**8**; 100 mg, 0.36 mmol),

NaN₃ (70 mg, 1.07 mmol), and NH₄Cl (58 mg, 1.07 mmol) in DMF (1 mL) was stirred at 90 °C in a sealed tube for 16 h. After cooling to room temperature, the mixture was poured onto H₂O and the resulting suspension was acidified to pH 2~3 with 10% aqueous HCl, stirred at room temperature for 30 min, collected, washed with H₂O, and dried to give **9** (95 mg, 82%) as a solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.02 (s, 1H), 8.44 (br s, 2H), 7.96 (d, *J* = 2.3 Hz, 1H), 7.75 (dd, *J* = 8.7, 2.3 Hz, 1H), 7.57 (d, *J* = 8.6 Hz, 1H), 3.07 (p, *J* = 6.9 Hz, 1H), 1.27 (d, *J* = 6.9 Hz, 6H). MS *m/z* 321.0 (M-H)⁺. HPLC 95%.

2-Amino-*N*-hydroxy-7-isopropyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carboximidamide (10). Literature citation for methodology (Barker and Crossley, 2005). Hydroxylamine hydrochloride (100 mg, 1.42 mmol) was added portion-wise to a suspension of NaHCO₃ (120 mg, 1.43 mmol) in H₂O (1 mL) and the mixture was stirred for 2 min resulting a clear solution. A suspension of 2-amino-7-isopropyl-5-oxo-5*H*-chromeno[2,3-*b*]pyridine-3-carbonitrile (**8**; 200 mg, 0.72 mmol) in EtOH (3.6 mL) was added to the above solution and the mixture was heated at reflux for 5 h. After cooling, the mixture was added to H₂O (15 mL) and stirred at room temperature for 10 min. The precipitated solids were collected, washed with H₂O, and dried to give **10** (205 mg, 92%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 10.06 (s, 1H), 8.70 (br s, 1H), 8.57 (s, 1H), 8.06 (br s, 1H), 7.94 (d, *J* = 2.3 Hz, 1H), 7.71 (dd, *J* = 8.7, 2.4 Hz, 1H), 7.53 (d, *J* = 8.6 Hz, 1H), 6.16 (s, 2H), 3.06 (p, *J* = 6.9 Hz, 1H), 1.26 (d, *J* = 6.9 Hz, 6H).

2-Amino-7-isopropyl-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-5*H*-chromeno[2,3-*b*]pyridin-5-one (11). Literature citation for methodology (Day et al., 2013). A suspension of **10** (45 mg, 0.14 mmol) and triphosgene (56 mg, 0.19 mmol) in *p*-dioxane (6 mL) was stirred at 100

°C for 4 h. The mixture was cooled to room temperature and poured into H₂O (20 mL). The resultant suspension was stirred at room temperature for 50 min and the solids were collected, washed successively with H₂O and DCM, and dried to leave **11** (38 mg, 78%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.20 (br s, 1H), 8.80 (s, 1H), 8.54 (br s, 1H), 7.95 (s, 1H), 7.75 (d, *J* = 8.6 Hz, 1H), 7.56 (d, *J* = 8.6 Hz, 1H), 7.48 (br s, 1H), 3.13 - 2.97 (m, 1H), 1.26 (d, *J* = 6.8 Hz, 6H). MS *m/z* 337.0951 (M-H)⁻. HPLC 63%, 19% (oxadiazolone isomers).

2-Amino-7-isopropyl-3-(1,2,4-oxadiazol-3-yl)-5H-chromeno[2,3-*b*]pyridin-5-one (12).

Literature citation for methodology (Huang et al., 2008). To a mixture of **10** (120 mg, 0.38 mmol) and triethyl orthoformate (3.0 mL, 18.06 mmol) in *p*-dioxane (3.0 mL) was added BF₃·Et₂O (2.7 mg, 0.02 mmol). The mixture was stirred at 80 °C for 1 h and after cooling diluted with ether (20 mL). The precipitated solid was collected, stirred with ether (20 mL) for 30 min, collected again and dried to give **12** (77 mg, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.83 (s, 1H), 9.09 (s, 1H), 8.05 (d, *J* = 2.2 Hz, 1H), 7.92 - 7.84 (m, 1H), 7.72 (d, *J* = 8.3 Hz, 1H), 3.14 - 3.10 (m, 1H), 1.29 (d, *J* = 7.0 Hz, 6H). MS *m/z* 323.1 (M+1)[±] and 321.1 (M-1)⁻. HPLC 86%.

Supplemental References

- Barker E and Crossley R. (2005). Indazole derivatives which interact with the G protein-coupled receptor family, and their preparation, pharmaceutical compositions, and use against BRS-3 receptor-related disorders. PCT Patent Application WO2005056532 A1.
- Bergmanis AA, Bonafoux D, Clare M, Crich JZ, Fletcher TR, Geng L, Hagen TJ, Hamper BC, Hanson GJ, Houdek SC, Huang H, Iula DM, Koszyk FJ, Lennon PJ, Liao S, Liao S, Metz S, Mohler SB, Nguyen M, Oburn DS, Owen TJ, Partis RA, Scates AM, Stealey MA, Tollefson MB, Vazquez ML, Weier RM, Wolfson SG and Xu X. (2003). Preparation of 4,5-dihydro-1H-benzo[g]indazole-3-carboxamides for the treatment of inflammation. PCT Patent Application WO2003024935 A2.
- Day R, Neugebauer W and Dory Y. (2013). Stable peptide-based furin inhibitors. PCT Patent Application WO2013029182 A1.
- Eastwood P, Gonzalez J, Paredes S, Fonquerna S, Cardús A, Alonso JA, Nueda A, Domenech T, Reinoso RF and Vidal B. (2010). Discovery of potent and selective bicyclic A2B adenosine receptor antagonists via bioisosteric amide replacement. *Bioorg Med Chem Lett* **20** (5): 1634–1637.
- Gilligan M, Humphries AC, Ladduwahetty T and Merchant KJ. (2006). Preparation of heteroarylsulfonyl stilbenes as 5-HT_{2A} receptor antagonists for the treatment of CNS diseases. PCT Patent Application WO2006095205 A1.
- Huang TL, Vanden Eynde J-J, Mayence A, Bacchi C, Donkor IO and Kode N. (2008). Bisbenzamidines and bisbenzamidoximes as parasiticides and their preparation, pharmaceutical compositions and use in the treatment of human African trypanosomiasis. PCT Patent Application WO2008070831 A2.

- Kimura T, Ohkawa N, Nakao A, Nagasaki T and Shimozato T. (2007). Preparation of cyclic tertiary amine compounds that inhibit inflammatory cytokine production, US Patent 20070049620 A1.
- Liang C, Koenig M, He Y and Holmberg P. (2008). 2,4-Diaminopyridine derivatives as inhibitors of focal adhesion kinase and their preparation, pharmaceutical compositions and use in the treatment of cancer. PCT Patent Application WO2008115369 A2.
- Nohara A, Ishiguro T, Ukawa K, Sugihara H, Maki Y and Sanno Y. (1985). Studies on antianaphylactic agents. 7. Synthesis of antiallergic 5-oxo-5H-[1]benzopyrano[2,3-b]pyridines. *J Med Chem* **28** (5): 559-568.
- Pfau R, Arndt K, Doods H, Huel N, Klinder K and Kuelzer R. (2010). Preparation of 3H-imidazo[4,5-c]pyridine-6-carboxamides as therapeutic inhibitors of enzymes belonging to the MAPEG family. PCT Patent Application WO2010034799 A1.
- Ren P, Liu Y, Li L, Chan K, Wilson TE, Castro AC, Evans CA and Snyder DA. (2012). Preparation of bicyclic heterocyclic compounds as kinase modulators. PCT Patent Application WO2012064973 A2.